Dopamine agonist monotherapy in early Parkinson's disease
Research output: Contribution to journal › Article
While levodopa therapy for Parkinson's disease is still considered the gold standard, motor complications are significant disadvantages of treatment. Monotherapy with dopamine agonists may present an alternative approach with a reduced likelihood of developing dyskinesias. Further studies are required before a definitive judgment can be made.
|Number of pages||4|
|Publication status||Published - 1 Jan 2003|